Nasdaq:US$16.45 (+0.58) | HKEX:HK$25.70 (+0.50) | AIM:£2.43 (+0.09)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.